Viewing data from:

WELIREG

NDA

BELZUTIFAN | N215383 | MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

1 strength4 unique patents5 unique exclusivities

Patent Timeline

4 unique patents, 5 exclusivities by expiration date

Active (4)TodayExclusivity

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

Today

Sep. 5, 2034

Sep. 5, 2034

Apr. 14, 2036

Jun. 30, 2042

NCE

Aug. 13, 2026

I-931

Dec. 14, 2026

I-968

May. 14, 2028

ODE-364

Aug. 13, 2028

I-994

Jun. 12, 2029

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

15 trials from ClinicalTrials.gov — 9 recruiting, 3 active, 2 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)NCT02974738	Phase 1	Active	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	120	2016-12-07 → 2026-10-08
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)NCT03401788	Phase 2	Active	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	50	2018-05-02 → 2027-04-29
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)NCT03634540	Phase 2	Active	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	118	2018-09-27 → 2027-02-26
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma NCT07840001	Phase 2	Not Yet Recruiting	Peter MacCallum Cancer Centre, Australia	30	2026-12 → 2030-04
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma NCT06234605	Phase 1	Recruiting	HiberCell, Inc.	80	2024-04-29 → 2027-11
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)NCT07049926	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	140	2025-07-20 → 2031-10-26
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)NCT07227402	Phase 3	Recruiting	Merck Sharp & Dohme LLC	904	2025-11-26 → 2032-02-27
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)NCT04924075	Phase 2	Recruiting	Merck Sharp & Dohme LLC	355	2021-08-12 → 2032-11-18
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)NCT07700758	Phase 2	Recruiting	Merck Sharp & Dohme LLC	15	2026-11-23 → 2034-01-02
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)NCT07489495	Phase 3	Recruiting	Merck Sharp & Dohme LLC	758	2026-04-09 → 2030-11-27

Source: ClinicalTrials.gov. Trials matched by ingredient name.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (1 FSS, 1 Big4)

Lowest Price

$22508.03

Highest Price

$29476.72

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00006-5331-01WELIREG 40MG TAB	$29476.72	FSS	Merck Sharp & Dohme LLC	05/31/2030
00006-5331-01WELIREG 40MG TAB	$22508.03	Big4	Merck Sharp & Dohme LLC	05/31/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Welireg (2024)

Total Spending

$205.5M

Total Claims

7,964

Beneficiaries

1,896

Avg Cost/Unit

$323.85

Spending Trend

$4.0M(2021)→$29.7M(2022)→$59.8M(2023)→$205.5M(2024)

YoY Change:-0.5%

5yr CAGR:+1.5%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs

4 active API suppliers hold Drug Master Files for this ingredient.

VALARY LAB PRIVATE LTDBELZUTIFAN

DMF 414232025

MSN LABORATORIES PRIVATE LTDBELZUTIFAN

DMF 414692025

APICORE LLCBELZUTIFAN

DMF 415152025

HETERO LABS LTDBELZUTIFAN PREMIX

DMF 419122025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

8 letters from Drugs@FDA

Date	Submission	Document
Sep 28, 2026	SUPPL -13	View Letter (PDF)
Jun 16, 2026	SUPPL -15	View Letter (PDF)
May 23, 2025	SUPPL -12	View Letter (PDF)
Apr 21, 2025	SUPPL -10	View Letter (PDF)
Apr 21, 2025	SUPPL -11	View Letter (PDF)
Mar 12, 2024	SUPPL -7	View Letter (PDF)
Dec 15, 2023	SUPPL -6	View Letter (PDF)
Aug 16, 2021	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 40MG

RLD

10 patents5 exclusivities▴

TABLET;ORAL | Approved: Aug 13, 2021

Patents (10)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
RE49948	Sep 5, 2034	—	Yes	Yes		—
RE49948	Sep 5, 2034	—	Yes	Yes		—
RE49948	Sep 5, 2034	—	Yes	Yes		—
RE49948	Sep 5, 2034	—	Yes	Yes		—
9908845	Sep 5, 2034	—	Yes	Yes		—
9908845	Sep 5, 2034	—	Yes	Yes		—
9908845	Sep 5, 2034	—	Yes	Yes		—
9908845	Sep 5, 2034	—	Yes	Yes		—
10335388	Apr 14, 2036	—	—	—		—
12358870	Jun 30, 2042	—	—	Yes	—	—

Exclusivities (5)

Code	Date	Status
I-931	Dec 14, 2026	< 1 year
I-968	May 14, 2028	Active
I-994	Jun 12, 2029	Active
NCE	Aug 13, 2026	Expired
ODE-364	Aug 13, 2028	Active